KLRA — Kailera Therapeutics Share News
0.000.00%
Last trade - 00:00Factbox: Weight-loss drug developers line up to tap lucrative market as competition heats up
China biotech's ingenuity extends to dealmaking
Factbox: Weight-loss drug developers line up to tap lucrative market as competition heats up
Brief: Kailera Therapeutics Announces Completion Of Enrollment In Kainetic Global Phase 3 Clinical Program Of Glp-1/Gip Receptor Dual Agonist Ribupatide Injection
Factbox: Weight-loss drug developers line up to tap lucrative market as competition heats up
Factbox: Weight-loss drug developers line up to tap lucrative market as competition heats up
Kailera Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
Kailera Therapeutics Inc expected to post a loss of 75 cents a share - Earnings Preview
U.S. STOCKS ON THE MOVE-Vera Therapeutics, Vera Therapeutics, Nvidia
Factbox: Race to launch weight-loss pills heats up as smaller players advance
U.S. STOCKS ON THE MOVE-Revolution Medicines, Vivani Medical, Nvidia
Factbox: Weight-loss drug developers line up to tap lucrative market as competition heats up
Kailera Therapeutics up after weight-loss drug meets main goal of late-stage trials in China
U.S. STOCKS ON THE MOVE-Nvidia, Crinetics Pharmaceuticals, Rivian Automotive
Kailera Therapeutics up after weight-loss drug meets main goal of late-stage trials in China
Kailera shares tumble on high nausea rates despite weight-loss drug's success (updated)
Kailera's GLP-1 drug meets main goal of late-stage trials
Kardigan surges in Nasdaq debut after upsized $400 million IPO (updated)
Brief: Kailera Therapeutics Says Phase 2 Ribupatide Oral Shows Up To 12.1% Mean Weight Loss At 26 Weeks